

CUMULATIVE INDEX 1992

Volume 10

March	EPIDURAL AND SPINAL ANALGESIA AND ANESTHESIA: CONTEMPORARY ISSUES, pages 1-210
June	CURRENT CONCEPTS IN ACUTE PAIN CONTROL, pages 211-451
September	CEREBRAL PROTECTION, RESUSCITATION, AND MONITORING: A LOOK INTO THE FUTURE OF NEUROANESTHESIA, pages 453-753
December	EMBOLISM I, pages 755-927

Note: Page numbers of issue and article titles are in **boldface** type

- Acetaminophen, for pediatric analgesia, 367
- Acidosis, intracellular, 457
- Acoustic neuroma, monitoring with sensory-evoked potentials (SEPs), 670-671
- Acute pain control. See *Pain control, acute*.
- Adenosine triphosphate, pain sensitization caused by, 251
- Adjuvants in epidural and spinal anesthesia, 13-30
- α_2 -adrenergic agents, 24-25
- alterations of physicochemical properties, carbonation and alkalization, 14-16
- dextrose and water, 16-17
- pharmacologic enhancement of anesthetic effect, 17-26
- warming of local anesthetics, 16
- definition of, 113
- epinephrine and other sympathomimetics, 17-24
- contraindications, 24
- in epidural analgesia for labor, 70-71
- history of use, 17-18
- intensity of analgesia and anesthesia, 19-20
- optimal dose, 21-22
- prolongation of duration of neural blockade, 18-19
- reduction and delay of systemic absorption, 19
- reduction of tachyphylaxis by, 21
- spinal cord blood flow and, 23-24
- systemic effects when injected into epidural space, 22
- used as a test dose, 20-21
- uterine effects, 23
- opioids, in epidural analgesia for labor, 71-72
- in epidural and spinal anesthesia, 25-26
- Adult respiratory distress syndrome (ARDS), 761, 762
- Afferent pathways, 221-223
- Age, and electroencephalographic monitoring, 700
- and outcome of cardiopulmonary resuscitation, 627-628
- Agonist-antagonist narcotics, 383. See also α_2 -Agonists.
- Air, as alternative test dose, 54
- identifying loss of resistance, 74
- Air embolism, 478-483
- adverse effects, 479-480
- caused by positive end expiratory pressure (PEEP), 812-813
- monitoring, 480-481
- positive end-expiratory pressure (PEEP), 482-483
- sitting position in posterior fossa surgery, 478-483
- treatment, 481-482

- Airway management, after head injury, 611-613
 in spinal cord surgery, 502-503, 503-504
- Alfentanil, for epidural postoperative analgesia, 328
- Alkalization of local anesthetics, 14-15
- α_2 -Adrenergic agents, as an adjuvant to epidural and spinal anesthesia, 24-25
- α_2 -Agonists, 312-315
 clonidine, 313-315, 330-332, 406
 dexmedetomidine, 315
 for epidural postoperative analgesia, 330-332
 for preventing urinary retention, 423
- Ambulation, for preventing deep vein thromboembolism, 836
- Amino acids, excitatory, and central sensitization, 259
- 21-Aminosteroids, 594
- AMPA receptor, 585, 588
- Analgesic agents, systemic. See *Systemic analgesic agents*.
- Analog Chromatic Continuous Scale, 360
- Aneurysms. See also *Subarachnoid hemorrhage therapy*.
 atrial septal aneurysm, 802, 805, 813-814
 cerebral aneurysm clipping, 671-672
 incidence, 521-522
 in posterior fossa, 474-475
- Anti-inflammatory agents, in critically ill patients, 398
 nonsteroidal, for pediatric analgesia, 367-368
 prevention of secondary hyperalgesia, 214
- Anticoagulation therapy, and antiplatelet therapy, 1-11. See also *Platelet aggregation inhibitors*.
 antiplatelet therapy, 6-7
 central neuraxial blockade and anticoagulants, 4-6
 clotting mechanism, 3
 complications, 1-2, 5-6
 direct anticoagulants, 3-4
 indirect anticoagulants, 2-3
 pharmacologic parameters, 9
 recommendations, 7-9
 thrombolytic therapy, 6
 for cerebral protection, 462
 for thromboembolism. See also *Thrombolytic therapy*.
 algorithms for patient management, 845-846
 coumarin, 834-835, 849
 dextran, 835-836
 dihydroergotamine (DHE) and heparin, 832-833
 heparin, compared with thrombolytic agents, 888, 889
 for deep vein thrombosis, 830-834
 dosage, 847
 in general surgery, 839-843
 guidelines for use, 849
 in gynecologic surgery, 842-843
 hemorrhage, as complication of, 843, 883, 885
 low molecular weight heparins, 830-832, 885
 in neurosurgery, 841
 in orthopedic surgery, 843
 with regional anesthesia, 856
 in trauma patients, 846
 treatment of pulmonary embolism, 881, 882-883, 885-886
 in urologic surgery, 841-842
 regional anesthesia and, 855-857
 full anticoagulation, 856
 intraoperative anticoagulation, 857
 low-dose anticoagulation, 856-857
 trauma patients, 845-846
 warfarin, 843, 849
- Antiplatelet therapy. See under *Anticoagulation therapy*.
- Apnea in neonates, as postoperative complication, 141-142
- Arachidonic acid, and cell destruction after ischemia, 582, 589-590
 pain sensitization caused by, 251
- Arachnoid cysts, 474
- Arnold-Chiari malformations, hydrocephalus and, 540
 preoperative neurologic assessment, 652-653
 surgery, 472
- Arteriovenous malformations, and pediatric neuroanesthesia, 556-559
 in posterior fossa, 475
- Aspartate, 259-260, 585, 586. See also *NMDA (N-methyl-D-aspartate) receptor*.
- Assessment of neurologic function. See *Preoperative assessment of neurologic function*.
- Astrocytomas, cerebellar, 472
- ATP, cerebral consumption of, 568-569, 570-571
 synthesis in the brain, 564-565
- Atrial septal abnormalities, 799-801
 atrial septal aneurysm, 802, 805, 813-814
 locations of defects (illustration), 800
 ostium primum, 801
 ostium secundum, 799, 801
 patent foramen ovale, 801-802
 sinus venosus, 801
- Atrial septum. See *Interatrial septum and systemic embolism*.

- Autotomy, in animals, 257-258
- B-mode ultrasonography, for diagnosis of
 deep vein thrombosis, 828-830
 duplex scanning, 828-829
- Backache, postpartum, 81
- BAEPs (Brain stem auditory-evoked potentials), 661, 667, 670-671
- Barbiturates, for cerebral protection, 460-461
 and electroencephalographic monitoring, 707
 for obstetric pain management, 384
- Baricity and spinal anesthesia, 31-43
 drugs and recommendations, 39-41
 duration, 38-39
 history, 31-33
 intrathecal drug spread, 33-38
 clinical interactions and, 37
 definitions, 33-34
 dosage, 34-35
 level of injection, 36
 minor differences in baricity, 37-38
 patient characteristics, 36
 patient posture, 35
 solution baricity, 34
 volume and rate of injection, 35-36
- Benzodiazepines, for cerebral protection, 465
 and electroencephalographic monitoring, 708-709
 for obstetric pain management, 384
 for pain control in critically-ill patients, 407
- β -Blockade, and test doses, 47
- Blood-brain barrier, and cerebral ischemia, 457-458
- Blood flow. *See Cerebral blood flow.*
- Blood patch, epidural, 169-173
 complications, 172-173
 ideal volume, 171
 mechanism of action, 171
 after neonatal spinal anesthesia, 142
 prophylactic blood patch, 171-172
- Blood transfusion, and risk of thromboembolic disease, 854
- Brachial plexus block, 350-352, 369, 401
- Bradykinin, pain sensitization caused by, 251, 253
- Brain edema. *See Cerebral edema.*
- Brain neoplasms, brain stem gliomas, 473
 future therapeutic methods, 723-724
- Brain stem auditory-evoked potentials (BAEPs), 661, 667, 670-671
- Bupivacaine, baricity, 40
 carbonation and alkalization, 15-16, 114
 combined with adjunct drugs, 70-72, 113-114, 156
 combined with morphine, 329-330
 continuous infusion of, 402
 in epidural anesthesia during labor, 65-66, 69-70, 108-109
 fetal and neonatal effects, 109-110
 history, 32-33
 in neonatal spinal anesthesia, 137, 140
 in obstetric pain management, 387
 and thromboembolic disease, 854
 warming of, 16
- Buprenorphine, oral administration, 272
- C-fiber neuropeptides, in central sensitization, 219-220, 259-260
 in peripheral sensitization, 213-214
- C-fos proto-oncogene, and central sensitization, 262-263
- Caffeine, as therapy for postdural puncture headaches, 168-169
- Calcitonin gene-related peptide, central sensitization and, 259-260
- Calcium, in cell physiology, 579-580
 and cerebral ischemia, 456
 entry into cells during ischemia, 581-582
 intracellular, and central sensitization, 260, 262
- Calcium channel antagonists, cerebral protection and resuscitation, 461, 583-585
 resuscitation of spinal cord injuries, 507
 subarachnoid hemorrhage therapy, 526-527, 532
- Calf vein thrombosis, 872
- Capsaicin, 315-316
- Carbon dioxide, and cerebral protection, 460
 and electroencephalographic monitoring, 700
- Carbonation and alkalization of local anesthetics, adjuvant effect, 14-16, 70
 in cesarean deliveries, 113-114
- Cardiopulmonary resuscitation and cerebral outcome, 619-643
 anesthesia and CPR, 630-631
 anesthetic-related deaths, 631
 history, 619-621
 in-hospital CPR, 625, 626-627
 near drowning, 630
 out-of-hospital CPR, 621-625
 patient selection for CPR, 634-636
 pediatric and neonatal CPR, 628-629
 survival improvement, 631-634
 trauma and CPR, 629-630

- Cardiovascular effects of systemic analgesics, clonidine, 314-315
 dezocine, 305
 ketorolac, 310
- Cardiovascular performance in embolism, 755-780
 anesthesia and hypertension, 775-776
 hemodynamic management, 771-776
 pulmonary vascular bed, 769-771
 right ventricle, 757-769
 anatomy and physiology, 758-761
 impact of therapy on performance, 766-769
 performance in pulmonary embolism, 757-758, 764-766
 resuscitation, 761-764
 vascular bed, 755-757
- Cardiovascular system, preoperative neurologic assessment of, 647
 response to head injury, 609-610, 648
- Carotid endarterectomy, monitoring with somatosensory-evoked potentials (SSEPs), 672
- Catecholamines, as adjunct to local anesthetics, 112-113
 as a test dose, 52-53
 treatment of right ventricular failure, 764
- Catheters, complications in epidural analgesia for labor, blood vessel puncture, 80
 failed or unsatisfactory block, 80-81
 postpartum backache, 81
 in continuous spinal anesthesia, breaking of catheters, 94
 complication of placement, 92, 94
 placement, 88-91
 small gauge catheters, 91
 spinal headaches and, 94-95
 32-gauge catheters, 92
- Cauda equina syndrome, 95, 97-101
- Cavernous angiomas, in posterior fossa, 475
- Cellular messengers, and central sensitization, 260-262
- Central rostral-caudal deterioration, after head injury, 605-606
- Central sensitization, 219-221, 254-263
 causes of, 219-220
 of dorsal horn neurons, 255-263
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 cellular messengers and, 260-262
 molecular events and, 262-263
 neurochemical mediators of sensitization, 259-260
 receptive field expansion, 255-257
 prevention of, 220-221
- as a result of tissue injury, 254-263
- Cerebellar infarction, 473
- Cerebellar tumors, 472-473
- Cerebellopontine angle tumors, 473-474, 670-671
- Cerebral aneurysm clipping, monitoring with sensory-evoked potentials (SEPs), 671-672
- Cerebral blood flow, and brain ischemia, 455-456
 after head injury, 609
 and intracranial pressure, 645-646
 in pediatric neuroanesthesia, 538-539
 regulation, 454
- Cerebral death, defined, 651
- Cerebral edema, after head injury, 609
 in pediatric neuroanesthesia, 539, 543-544
- Cerebral ischemia, 575-577
 blood-brain barrier, 457-458
 and calcium, 456
 calcium influx, 581-582
 cellular physiology, 577-580
 cerebral blood flow, 455-456
 electroencephalographic monitoring, 701-702, 709-711
 excitotoxic damage, 456-457
 free radicals, 457
 intracellular acidosis, 457
 membrane changes, 581
 mitochondrial dysfunction, 581
 pathophysiology, 455, 580-595
 resuscitation after prolonged ischemia, 575-577
 secondary consequences, 576
 selective vulnerability, 576-577
 vascular changes, 580-581
- Cerebral protection, resuscitation, and monitoring, cardiopulmonary resuscitation and cerebral outcome, 619-643
 anesthesia and CPR, 630-631
 history, 619-621
 in-hospital CPR, 625, 626-627
 near drowning, 630
 out-of-hospital CPR, 621-625
 patient selection for CPR, 634-636
 pediatric and neonatal CPR, 628-629
 survival improvement, 631-634
 trauma and CPR, 629-630
 cerebral protection and neuroanesthesia, 453-469
 anesthetics and cerebral protection, 462-465
 cerebral physiology, 454-455
 methods for cerebral protection, 458-462
 pathophysiology of cerebral injury, 455-458

- electroencephalographic monitoring, 683-718
 clinical correlation, 699-703
 depth of anesthesia, 703-709
 interpretation, 690-699
 ischemia monitoring, 709-711
 measurement systems, 685-690
 physiology, 684-685
- energy metabolism and ion transport, 563-573
 cost of ion transport, 568-571
 oxidative and glycolytic ATP generation, 563-565
 regional metabolism, 565-566
 threatened energy failure, 566-568
- evoked potentials, 657-681
 classification and common modalities, 658-659
 electrophysiologic basis, 657-658
 intraoperative monitoring, 673-674
 motor-evoked potential, 659-660, 664, 667, 668, 669
 prevention of neurologic injury, 669-673
 sensory-evoked potential, 660-663, 665-669
- future of neuroanesthesia, 727-744
 cerebral protection, 733-735
 drug delivery systems, 738-739
 financial concerns, 736-737
 history of anesthesiology, 729-732
 intracranial pressure, 730-731
 monitoring, 735-737
 neuroanesthesiologists, 732-733
 stroke, 738
- future of neurosurgery, 719-726
 brain tumors, 723-724
 enhancement of neurologic function, 722
 epilepsy, 721
 ethical concerns, 719-720
 pain, 725
 trauma, 725
 vascular disease, 722-723
- head injury, 603-617
 anesthetic management, 611-614
 classification, 603-604
 neurologic assessment, 605-611
 pathophysiology, 604-605
- pediatric neuroanesthesia, 537-562
 anesthetic considerations, 541-544
 arteriovenous malformations, 556-559
 intracranial pressure, 537-540, 541
 myelodysplasia, 547-550
 pathophysiology, 540-541
 physiology, 537-540
 supratentorial procedures, 550-555
 ventricular shunts, 545-547
- posterior fossa surgery, 471-491
 air embolism, 478-483
 anatomy of posterior fossa, 471-472
 anesthesia, 483-487
 congenital malformations, 472
 intra- and extra-axial lesions, 472-474
 positioning and intraoperative considerations, 476-478
 preoperative assessment, 475-476
 vascular lesions, 474-475
- preoperative assessment of neurologic function, 645-656
 autonomic nervous system function, 648
 imaging techniques, 648-649, 651, 653
 intracranial pressure, 645-647
 respiratory and cardiovascular centers, 647-648
 specific disorders, 650-653
- resuscitation, 575-601
 cellular physiology, 577-580
 ischemia, 575-577
 pathophysiology of ischemia, 580-595
- spinal cord surgery anesthesia, 493-519
 acute spinal cord injury, 503-508
 anatomy and physiology, 493-501
 decompression of spinal cord, 501-503
 scoliosis, 508-509
 thoracoabdominal aorta surgery, 509-510
- subarachnoid hemorrhage therapy, 521-536
 anesthetic management, 529-531
 cerebral protection, 531-532
 clinical presentation, 524
 history and pathophysiology, 521-524
 preoperative diagnosis, 524-525
 surgical management, 525-529
- Cerebrospinal fluid, increased intracranial pressure after head injury, 607-608
 pediatric neuroanesthesia, 539-540
- Cerebrovascular accident, and patent foramen ovale, 810, 812
- Cervical epidural steroid therapy. *See Steroid therapy, epidural*
- Cervical plexus block, in infants and children, 368
- Cesarean delivery with neuraxial blockade, 103-127
 epidural anesthesia, 103-117
 adjuncts to local anesthetics, 112-115
 alteration of pH, 113-114
 bupivacaine, 109-110
 carbonation of local anesthetics, 113-114
 catecholamines as adjuvants, 112-113
 chloroprocaine, 110-111
 complications, 105-106
 dural puncture, 116-117

- Cesarean delivery with neuraxial blockade (*Continued*)
 epidural venous cannulation, 105-106
 fetal and neonatal effects, 109-111
 intraoperative management, 111
 lidocaine, 110
 local anesthetic toxicity, 108-109
 maintenance of blockade, 111-112
 narcotics as adjuvants, 114-115
 nausea and vomiting, 107-108
 physiologic considerations, 106
 postoperative complications, 115-116
 preoperative management, 106-107
 technical considerations, 104-105
 spinal anesthesia, 117-121
 advantages, 117-118
 complications, 118-120
 local anesthetics, 120-121
 physiologic considerations, 118-120
 technical considerations, 117-118
- Chest x-ray, for diagnosis of pulmonary embolism, 879-880
- Children's Hospital of Eastern Ontario Pain Scale, 360
- Chloroprocaine, in epidural anesthesia during labor, 69-70
 fetal and neonatal effects, 110-111
 for obstetric pain management, 387-388
- Chondrosarcomas, 474
- Chordomas, 474
- Choroid plexus neoplasms, 473
- Clivus, lesions of, 474
- Clonidine, for acute pain control, 313-315
 as an adjuvant to epidural and spinal anesthesia, 24-25, 156, 330-332, 406
 hemodynamic and respiratory effects, 314-315
 pharmacokinetics, 315
- Coagulopathy, in head injury, 611
- Codeine, for pediatric analgesia, 365-366
- Coma, Glasgow Coma Scale (GCS), 603-604, 651, 652
 preoperative neurologic assessment, 651
- Computed tomography, in preoperative neurologic assessment, 649-650
- Congestive heart failure, and pediatric neuroanesthesia, 556, 557, 558
- Continuous infusion epidural anesthesia, in labor, compared with intermittent top-ups, 74-76
 opioids as adjuvants, 76-77
- Continuous spinal anesthesia, 87-102
 advantages and disadvantages, 87-88
 catheter placement, 88-91
 cauda equina syndrome, 95, 97-101
 complications of catheter placement, 92, 94
 indications and contraindications, 88
- local anesthetics and intrathecal opioids, 89, 91
 small gauge catheters, 91
 spinal canal models, 97-100
 spinal headache, 94-96
 summary, 101
 32-gauge catheter, 92-93
- Contrast two-dimensional thoracic echocardiography, 814-815
- Convulsions, caused by regional analgesia, 390
- Corticosteroids. *See Steroids.*
- Coumadin, and neuraxis blockade, 4
- Coumarin anticoagulation, interactions with other drugs, 849
 preventing deep vein thromboembolism, 834-835
- Craniofacial procedures, neuroanesthetic considerations, 554
- Craniopharyngioma, neuroanesthetic considerations, 554-555
- Craniosynostosis, neuroanesthetic considerations, 553
- Critically ill patients, pain control in, assessing the patient's pain, 397-398
 complications, 409-410
 hemodynamic stability, 410-411
 length of hospital stay, 411
 local anesthetic techniques, 399-401
 nonsteroidal anti-inflammatory agents, 398
 pain-related behavior, 395-396
 regional blocks, 399-401
 spinal analgesia, 401-406
 epidural or subarachnoid blocks, 401-406
 transcutaneous electrical nerve stimulation, 401
 summary, 411
 systemic analgesia, 407-411
 opioids, 407-409
 sedation, 407
- Decompression sickness, and systemic embolism, 813
- Deep vein thrombosis, 823-867. *See also Pulmonary embolism*
 anesthesia and, 851-857
 blood transfusion, 854
 effects on coagulation, 853-854
 local anesthesia, 854-855
 lower extremity blood flow, 852
 regional anesthesia and anticoagulant therapy, 855-857
 regional compared with general anesthesia, 853
 coumarin anticoagulation, 834-835, 849

- dextran anticoagulation, 835-836
 diagnosis, 824-830, 876
 B-mode ultrasonography, 828-830
 combined impedance plethysmography and ^{125}I -fibrinogen scanning, 825-826
 Doppler ultrasonography, 827, 876
 ^{125}I -fibrinogen uptake test, 825-826, 876
 impedance plethysmography, 826-827, 876
 noninvasive procedures, 825-830, 876, 877
 venography, 825, 876
 heparin anticoagulation, 830-834, 839-843, 846, 847, 849, 856
 mechanical methods of prevention, 836-838
 prevention, 830
 risk factor assessment, 838-847
 general risk factors, 823-824, 870-871
 general surgery, 839-840
 gynecologic surgery, 842-843
 high-risk patients, 839, 871
 low-risk patients, 838-839, 870
 moderate-risk patients, 838-839, 870
 neurosurgery, 840-841
 orthopedic surgery, 843-844
 trauma patients, 844-846
 urologic surgery, 841-842
 treatment, 847-851
 inferior vena cava interruption, 848-850
 surgical treatment, 851
 warfarin anticoagulation, 847-848, 849
 Descriptor Differential Scale, 239, 240
 Dexmedetomidine, 315
 Dextran anticoagulation, compared with low molecular weight heparins, 834
 complications, 835-836
 orthopedic surgery, 843
 preventing deep vein thromboembolism, 835-836
 Dextromethorphan, 462
 Dextrose, as an adjuvant in local anesthetics, 16-17
 Dezocine, 299-307
 abuse potential, 300-302
 adverse effects, 307
 analgesic activity, 302-303
 cardiovascular effects, 305
 clinical trials, 305-307
 increased analgesia following morphine administration, 304-305
 pharmacokinetics, 302
 respiratory effects, 303-305
 Diabetes insipidus, after head injury, 614
 post-craniopharyngioma surgery, 555
 Digital subtraction angiography (DISA), 816
 Dihydroergotamine (DHE), combined with heparin anticoagulation, 832-833
 Dobutamine, for treatment of pulmonary embolism, 768, 774, 881
 Dopamine, for treatment of pulmonary embolism, 768, 881
 Doppler echocardiography, of interatrial septum, 815-816
 Doppler ultrasonography, for diagnosis of deep vein thrombosis, 827, 876
 Dorsal horn neurons, 217-221
 central sensitization of, 219-221
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 causes of, 219-220
 cellular messengers and, 260-262
 clinical significance, 220-221
 molecular events and, 262-263
 neurochemical mediators of sensitization, 259-260
 receptive field expansion, 255-257
 classes of neurons responsive to nociceptive stimuli, 217-218
 organization of, 217-218
 spinal afferent processing, 218-219
 wide dynamic range (WDR) neurons, 218-219
 Drowning, and survival after CPR, 630
 Dural puncture, inadvertent, 79, 116-117.
 See also *Postdural puncture headaches*.
 Dyspnea, following pulmonary embolism, 783
 Echocardiography, color Doppler imaging, 815-816
 contrast two-dimensional thoracic echocardiography, 814-815
 diagnosis of paradoxical embolism, 810
 interatrial septal motion, 805
 intravascular ultrasound, 816
 transesophageal echocardiography, of interatrial septum, 798, 815-816
 "straddling" thrombi across interatrial communication, 810, 811
 two-dimensional, 814
 Edema. See *Cerebral edema*
 Elastic stockings, for preventing deep vein thromboembolism, 836
 Elderly patients, problems with test doses, 52
 Electrocardiography, for diagnosis of pulmonary embolism, 879-880
 Electroencephalographic monitoring, 683-718

- Electroencephalographic monitoring (*Continued*)
- amplifiers, 687-688
 - artifact detection, 698-699
 - artifact waveforms, 692
 - automated alarms and diagnosis, 699
 - clinical correlation, 699-703
 - depth of anesthesia, 703-709
 - electrodes, 685-689
 - filters, 689-690
 - frequency-domain analysis, 695
 - interpretation, 690-699
 - ischemia monitoring, 709-711
 - measurement systems, 685-690
 - physiology, 684-685
 - in preoperative neurologic assessment, 650-651
 - quantitative analysis, 691, 693
 - spectral displays, 696-698
 - statistical basis of automated processing, 691
 - time-domain analysis, 693-695
- Electrolyte balance, and
electroencephalographic monitoring, 700
- Embolism and anesthesia, cardiovascular performance in embolism, 755-780
- hemodynamic management, 771-776
 - pulmonary vascular bed, 769-771
 - right ventricular performance, 757-769
 - vascular bed, 755-757
- deep vein thrombosis, 823-867
- anesthesia and, 851-857
 - coumarin anticoagulation, 834-835
 - dextran anticoagulation, 835-836
 - diagnosis, 824-830
 - heparin anticoagulation, 830-834
 - mechanical methods of prevention, 836-838
 - prevention, 830
 - risk factor assessment, 838-847
 - treatment, 847-851
- interatrial septum and systemic embolism, 795-822
- atrial septal abnormalities, 799-802
 - clinical implications, 816-818
 - development of septum, 795-798
 - imaging of interatrial communications, 814-816
 - interatrial septal communications, 805-814
 - normal interatrial septum, 798-799
 - paradoxical embolism, 809-812
 - physiology and pathophysiology, 803-809
- pulmonary effects of pulmonary embolism, 781-793
- acute thromboembolization, 782-789
 - chronic thromboembolization, 789-791
 - gas exchange, 784-789, 790-791
 - lung mechanics, 782-784, 789-790
- pulmonary thromboembolism, 869-904
- anesthetic effects, 894-895
 - anesthetic management, 891-892
 - cardiopulmonary changes after, 878-879
 - chronic pulmonary thromboemboli, 895-896
 - definitive treatment, 882-893
 - diagnosis, 872-876
 - heparin therapy, 882-883, 885-886
 - inferior vena cava procedures, 892-893
 - intraoperative presentation of, 893-894
 - origin of emboli, 871-872
 - pulmonary embolectomy, 889-891
 - risk factors, 870-871
 - signs and symptoms, 876-878
 - supportive treatment, 880-882
 - thrombolytic therapy, 886-889
 - transvenous catheter embolectomy, 892
- EMLA cream, 361, 363
- Endocrine diseases, and
electroencephalographic monitoring, 700-701
- Energy metabolism and ion transport, 563-573
- energetic cost of ion transport, 568-571, 578
 - energy changes and ionic homeostasis, 456
 - hypermetabolism after head injury, 609-610
 - ion homeostasis, 578-580
 - oxidative and glycolytic ATP generation, 563-565
 - regional metabolism, 565-566
 - threatened energy failure, 566-568
- Ependymal neoplasms, 473
- Ephedrine, as alternative test dose, 54-55
- and thromboembolic disease, 853
- Epidermoids, 474
- Epidual analgesia, in critically ill patients, 402-406
- catheter placement, 402
 - combined local anesthetic-opioid infusions, 406
 - continuous local anesthetic, 402
 - continuous opioid infusions, 406
 - opioids alone, 403-406
 - other agents, 406
- in infants and children, 371-372
- for obstetric pain management, 385-389
- choice of local anesthetic, 387-388

- contraindications, 389
- management, 388-389
- postoperative, 321-337
 - alfentanil, 328
 - α_2 -agonists, 330-332
 - fentanyl, 326-327
 - local anesthetics, 321-324
 - meperidine, 325-326
 - morphine, 324-325
 - narcotic agonist-antagonists, 328-329
 - opioid-local anesthetic combinations, 329-332
 - opioids, 324-328
 - sufentanil, 327-328
- and thromboembolic disease, coagulation effects, 853-854
- effect in deep vein thromboembolism, 894-895
- Epidural and spinal anesthesia, adjuvants and, 13-30
 - α_2 -adrenergic agents, 24-25
 - alteration of local anesthetics, 14-17
 - carbonation and alkalization, 14-16
 - dextrose and water, 16-17
 - epinephrine and other sympathomimetics, 17-24
 - opioids, 25-26
 - pharmacologic enhancement of local anesthetic effects, 17-24
 - warming of local anesthetics, 16
- anticoagulants and antiplatelet therapy, 1-11
 - anticoagulants, 2
 - antiplatelet therapy, 6-7
 - central neuraxial blockade and anticoagulants, 4-6
 - direct anticoagulants, 3-4
 - indirect anticoagulants, 2-3
 - recommendations, 7-9
 - thrombolytic therapy, 6
- baricity and spinal anesthesia, 31-43
 - drugs and recommendations, 39-41
 - duration, 38-39
 - history, 31-33
 - intrathecal drug spread, 33-38
- cesarean delivery with neuraxial blockade, 103-127
 - epidural anesthesia, 103-117
 - spinal anesthesia, 117-121
 - summary, 121-122
- continuous spinal anesthesia, 87-102
 - advantages and disadvantages, 87-88
 - catheter placement, 88-91
 - cauda equina syndrome, 95, 97-101
 - complications of catheter placement, 92, 94
 - indications and contraindications, 88
 - local anesthetics and intrathecal opioids, 89, 91
 - small gauge catheters, 91
 - spinal headache, 94-96
 - summary, 101
 - 32-gauge catheter, 92-93
- intraspinal opioid analgesia, 145-162
 - benefits, 146-147
 - choice of opioids, 150-151
 - complications, 154-155
 - contraindications, 154
 - drug combinations, 156-157
 - economic issues, 157
 - history, 145-146
 - indications, 146-149
 - patient-controlled analgesia, 147-149
 - patient monitoring issues, 151-153
 - postoperative analgesia, 149-150
 - subarachnoid vs epidural administration, 147
 - technical considerations, 149-155
- labor and epidural analgesia, 59-85
 - anatomy of epidural space, 61-63
 - anesthesia for delivery, 78
 - benefits, 60-61
 - catheter-related complications, 80-81
 - caudal block, 69
 - complications, 78-79
 - contraindications, 68
 - epinephrine as adjuvant, 70-71
 - equipment, 73
 - history, 59-60
 - identifying loss of resistance, 74
 - indications for use, 66-68
 - informed consent, 72-73
 - intermittent top-ups vs continuous infusion, 74-76
 - local anesthetics, 69-72
 - midline or paramedian approach, 68-69
 - neurologic complications, 81
 - opioids as adjuvants, 71-72, 76-77
 - patient-controlled analgesia, 77-78
 - pH adjustment of local anesthetics, 70
 - philosophy, 60
 - physiologic effects, 63-65
 - practical aspects, 72-78
 - progress of labor, 65-66
 - spinal epidural approach, 69
 - techniques, 68-69
 - test dose, 74
- lumbar and cervical epidural steroid therapy, 179-203
 - cervical epidural steroids, 187-191
 - complications, 197-200
 - history, 180-181
 - lumbar epidural steroids, 181-187
 - mechanism of action, 192-197
 - opiates combined with epidural steroids, 191-192
 - summary, 200-201

- Epidural and spinal anesthesia (*Continued*)
 neonatal spinal anesthesia, 129-144
 anatomic considerations, 131-132
 apnea as postoperative complication, 141-142
 choice of drugs, 137
 history, 129-130
 indications, 130-131
 postlumbal puncture headaches, 142
 review of clinical experience, 138-141
 summary, 142-143
 technical details, 132-137
 postdural puncture headaches, 163-178
 clinical presentation, 164-165
 pathophysiology, 163-164
 prevention, 165-167
 spontaneous low cerebral spinal fluid pressure headache, 174
 summary, 174
 treatment, 167-173
 unusual managements, 173-174
 test doses, 45-58
 alternatives, 53-56
 in anesthetized patients, 52-53
 β -blockades and, 47-48
 in elderly patients, 52
 epinephrine as standard test dose, 45-46
 in pregnant patients, 48-52
 problems, 47-53
 summary, 55-56
 Epidural blood patch. See *Blood patch, epidural*.
 Epidural hematoma, 115, 855, 856
 Epidural space, anatomy of, 61-63
 Epidural test doses. See *Test doses*.
 Epilepsy surgery, future trends, 721
 pediatric neuroanesthesia, 555
 preoperative neurologic assessment, 650
 Epinephrine, effect on local anesthetics, 349
 and thromboembolic disease, 853, 881
 Epinephrine and other sympathomimetics, 17-24
 contraindications, 24
 history of use, 17-18
 intensity of analgesia and anesthesia, 19-20
 during labor, as adjuvant to local anesthetics, 70-71
 optimal concentration and dose, 21-22
 prolongation of duration of neural blockade, 18-19
 reduction and delay of systemic absorption, 19
 reduction of tachyphylaxis, 21
 spinal cord blood flow, 23-24
 systemic effects when injected into epidural space, 22
 as a test dose, 20-21
 problems in pregnant patients, 48-52
 standard test dose, 45-46
 uterine effects, 23
 Ethical concerns in neurosurgery, 719-720
 Etomidate, for cerebral protection, 465
 and electroencephalographic monitoring, 708
 Eutectic mixture of local anesthetic (EMLA) cream, 361, 363
 Evoked potentials. See *Motor-evoked potentials (MEPs)*; *Sensory-evoked potentials (SEPs)*; *Somatosensory-evoked potentials (SSEPs)*.
 Excitatory amino acids, ischemic damage, 456-457, 532, 585-589
 spinal cord damage, 407
 Femoral vein thrombi, 872
 Fentanyl. See also *Transdermal therapeutic system (TTS)-fentanyl*.
 for epidural postoperative analgesia, 326-327
 for obstetric pain management, 382
 for pediatric analgesia, 364-365
 and pulmonary embolism, 775
 Fetus, benefits of lumbar epidural anesthesia, 61, 67
 fetal distress caused by epinephrine, 49-50
 Flexion reflexes, alterations in, 257
 Fluid management, after head injury, 613-614
 pediatric neuroanesthesia, 543-544, 552
 posterior fossa surgery, 486-487
 volume administration, as therapy for pulmonary embolism, 767, 880
 Fourth ventricle tumors, 473
 Free fatty acids, and cell destruction, 581-582, 590
 Free radical scavengers, for cerebral protection, 462, 593-594
 resuscitation of spinal cord injuries, 507
 Free radicals, and cerebral ischemia, 457, 590-594
 production of, 591-592
 Frequency-domain analysis, of electroencephalograms, 695
 Future of neuroanesthesia. See *Neuroanesthesia, future of*.
 Future of neurosurgery. See under *Neurosurgery*.
 Gas exchange, following pulmonary embolism, in acute thromboembolization, 784-789

- in chronic embolization, 790-791
- hypocapnia, 784
- shunts, 784, 786, 788
- ventilation/perfusion (VA/Q) inequality, 784-789
- General anesthesia, and thromboembolic disease, compared with regional anesthesia, 851-853
 - lower extremity blood flow, 852
- Glasgow Coma Scale (GCS), 603-604, 651, 652
- Glucose, cerebral energy metabolism requirements, 563-566
 - for cerebral protection, 459, 734
 - and electroencephalographic monitoring, 701
 - homeostasis, in pediatric patients, 544
- Glutamate, and central sensitization, 259-260
 - and ischemic damage, 585-589
- Glycine binding, and excitatory amino acid neurotransmitters, 586, 588
- GM, ganglioside, for resuscitation of spinal cord injuries, 508
- Greenfield filter, for prevention of pulmonary emboli, 850, 893
- Gynecologic surgery, and risk of deep vein thrombosis, 842-843
- Halothane, and electroencephalographic monitoring, 705
- Head injury, 603-617
 - airway management, 611-613
 - anesthetic management, 611-614
 - brain edema, 609
 - cardiovascular and metabolic response, 609-610
 - central rostral-caudal deterioration, 605-606
 - cerebral blood flow, 609
 - classification, 603-604
 - coagulopathy, 611
 - fluid management, 613-614
 - intracranial pressure, 607-608
 - neurologic assessment, 605-611
 - pathophysiology, 604-605
 - pulmonary response, 610-611
 - uncal herniation, 606-607
- Headaches. *See Postdural puncture headaches.*
- Hemangioblastomas, 472-473
- Hematomas, cerebellar, 473
 - epidural, 115, 855, 856
 - intracranial, 604-605
- Hemodilution, for cerebral protection, 459-460
- Hemodynamic management of pulmonary embolism, 771-776
- Hemodynamic result of pulmonary embolism, 770-771, 879
- Hemodynamic stability, after epidural opioids, 410-411
- Heparin anticoagulation, combined with dihydroergotamine (DHE), 832-833
 - compared with thrombolytic agents, 888, 889
 - in deep vein thrombosis, 830-834, 839-843, 846, 847, 849, 856
 - in general surgical procedures, 839-840
 - guidelines for therapy, 849
 - in gynecologic surgery, 842-843
 - hemorrhage, as complication of, 843, 883, 885
 - low-dose heparin, 830-832
 - low molecular weight heparins, 833-834, 885
 - and neuraxis blockade, 3-4, 5-6
 - in neurosurgery, 841
 - in orthopedic surgery, 843
 - overlapping heparin and warfarin therapy, 847
 - in pulmonary embolism, 881, 882-883, 885-886
 - regional anesthesia and, 856-857
 - thrombocytopenia and, 848, 885
 - in trauma patients, 846
 - urologic surgery, 841-842
- Hip fractures, and deep vein thrombosis, 844-845, 846, 870
- Histamine, as cause of pain sensitization, 251, 253, 254
- Hydralazine, for treatment of pulmonary embolism, 768, 773-774, 882
- Hydrocephalus, neonatal, 540, 547
- Hyperalgesia, secondary, caused by inflammatory peptides, 214
 - following tissue injury, 248
 - preventing, 214
 - spread by central sensitization, 254-255
- Hyperbaric solutions. *See Baricity and spinal anesthesia.*
- Hyperoxia, for cerebral protection, 460
- Hypertension, induced, for cerebral protection, 459, 734-735
- Hypocapnia, following pulmonary embolism, 784, 878
- Hypotension, induced, monitoring with sensory-evoked potentials (SEPs), 673
 - posterior fossa surgery, 487
 - spinal cord surgery, 501, 508-509
- Hypotension, secondary to analgesia, 390, 402, 404
- Hypothermia, causing metabolic arrest, 570

- Hypothermia** (*Continued*)
 for cerebral protection, 458-459, 733-734
 and electroencephalographic monitoring, 703
 monitoring with somatosensory-evoked potentials (SSEPs), 673
 in pediatric patients, 544
 resuscitation of spinal cord injuries, 506-507
- Hypoxemia**, following pulmonary embolism, 878
- Hypoxia**, cerebral metabolism and, 569-570
 and electroencephalographic monitoring, 701-702
- ¹²⁵I-fibrinogen uptake test, combined with impedance plethysmography, 826-827
 diagnosis of deep vein thrombosis, 825-826, 876
- Ilioinguinaliohypogastric block**, 369-370
- Imaging techniques**, echocardiography, 814-816
 intravascular ultrasound, 816
 intravenous digital subtraction angiography, 816
 magnetic resonance imaging (MRI), 816
- Impedance plethysmography**, combined with ¹²⁵I-fibrinogen uptake test, 826-827
 diagnosis of deep vein thrombosis, 826-827, 876
- Inadvertent dural puncture**. See *Dural puncture, inadvertent*.
- Indomethacin**, for pediatric analgesia, 367
- Infants and children**, pain control in. See *Pediatric pain control*.
- Inferior vena cava**, as origin of emboli, 872
 prevention of thromboembolism, 848-850, 892-893
 Greenfield filter, 850, 893
 indications for, 850
- Inflammation**, 248
 and pain sensitization, 251-254
- Inflammatory peptides**, as cause of secondary hyperalgesia, 214
- Informed consent**, during labor, 72-73
- Inhalational analgesia**, for obstetric pain management, 381-382
- Inotropic agents**, dobutamine, 768, 774, 881
 dopamine, 768, 881
 effect on right ventricle, 764
 following pulmonary embolism, 880-881
 isoproterenol, 53, 767, 774, 782, 880-881
 norepinephrine, 768
- Intensive care patients**. See *Critically ill patients, pain-control in*.
- Interatrial septum and systemic embolism**, 795-822
 atrial septal abnormalities, 799-802
 atrial septal aneurysm, 802
 atrial septal defect, 799-801
 patent foramen ovale, 801-802
 clinical implications, 816-818
 decompression sickness and, 813
 development of septum, 795-798
 imaging of interatrial communications, 814-816
 interatrial septal communications, 805-814
 paradoxical embolism, 809-812
 postural change and, 807
 shunting, 805-809
 motion of septum, 805
 normal interatrial septum, 798-799
 physiology and pathophysiology, 803-809
 transesophageal echocardiogram, 798
- Intercostal nerve blocks**, 344-346, 369, 399-400
- Interpleural analgesia**, in critically ill patients, 400-401
 in infants and children, 368-369
 regional block techniques, 346-350
 technique, 349-350
 in thoracotomy, 347-349
- Intracranial hematomas**, 604-605
- Intracranial pressure**, after head injury, 607-608
 imaging modalities, 647, 649-650
 improved therapy for, 729-731
 pediatric neuroanesthesia, 537-540, 541
 preoperative assessment, 645-647
 shifts of intracranial contents, 646-647
- Intraspinal opioid analgesia (IOA)**. See *Opioids*.
- Intravenous digital subtraction angiography (DISA)**, 816
- Intravenous regional block**, in infants and children, 369
- Ion transport**. See *Energy metabolism and ion transport*.
- Iron chelation**, for cerebral protection, 462
- Ischemia**. See *Cerebral ischemia*.
- Isoflurane**, for cerebral protection, 462-463
 and electroencephalographic monitoring, 705
 posterior fossa surgery, 484

- subarachnoid hemorrhage surgery, 531-532
- Isoproterenol, as alternative test dose, 53
- treatment of pulmonary embolism, 767, 774, 782, 880-881
- Kainate receptors, 585
- Ketamine, 384, 461, 462, 532, 708
- Ketanserin, following pulmonary embolism, 882
- Ketones, in cerebral metabolism, 564
- Ketorolac, 307-312, 367-368
- adverse effects, 309-310, 312
- clinical trials, 310-312
- mechanism of action, 307
- for pediatric analgesia, 367-368
- pharmacokinetics, 308-309
- respiratory and cardiovascular effects, 310
- structure, 308
- Kyenuric acid, 462
- Labor and epidural analgesia, 59-85
- anatomy of epidural space, 61-63
- benefits, 60-61
- catheter-related complications, blood vessel puncture, 80
- failed or unsatisfactory block, 80-81
- postpartum backache, 81
- complications, inadvertent dural puncture, 79
- maternal hypotension, 78-79
- total or high spinal block, 79
- contraindications, 68
- equipment and related factors, 73
- history, 59-60
- identifying loss of resistance, 74
- indications for use, 66-68
- informed consent, 72-73
- intermittent top-ups vs continuous infusion, 74-76
- local anesthetics, bupivacaine, 69-70
- epinephrine as adjuvant, 70-71
- opioids as adjuvant, 71-72
- pH adjustments, 70
- neurologic complications, 81
- opioids added to continuous infusions, 76-77
- patient-controlled analgesia, 77-78
- philosophy, 60
- physiologic effects, 63-65
- practical aspects, 72-78
- progress of labor, 65-66
- techniques, caudal block, 69
- midline or paramedian approach, 68-69
- spinal epidural approach, 69
- test dose, 48-52, 74
- Language descriptive of pain. See *Measurement of pain.*
- Lidocaine, for cerebral protection, 463, 465
- in epidural anesthesia for labor, 69
- fetal and neonatal effects, 110
- in neonatal spinal anesthesia, 137
- for obstetric pain management, 387
- posterior fossa surgery, 484
- and thromboembolic disease, 854
- Lidoflazine, for cerebral resuscitation, 583
- Local anesthetics, as adjuvants, alteration of pH, 113-114
- carbonation and alkalization, 14-16
- catecholamines, 112-113
- during cesarean delivery, 112-115
- dextrose and water, 16-17
- narcotics, 114-115
- warming of local anesthetics, 16
- as alternative test doses, 53
- in continuous spinal anesthesia, 89, 91
- in critically ill patients, 399-401
- effect of epinephrine, 349
- for epidural analgesia, 321-324
- combined with opioids, 329-332, 406
- in epidural analgesia for labor, 69-72
- bupivacaine, 69-70
- epinephrine as adjuvant, 70-71
- pH adjustment, 70
- in epidural anesthesia for cesarean delivery, choice of local anesthetics, 107-108
- fetal and neonatal effects, 109-111
- toxicity, 108-109
- hyperalgesia delayed by, 252
- in infants and children, 368
- pharmacologic enhancement of analgesia and anesthesia, α_2 -adrenergic agents, 24-25
- by epinephrine and other sympathomimetics, 17-24
- opioids, 25-26
- in spinal anesthesia for cesarean delivery, 120-121
- and thromboembolic disease, 854-855
- for wound infiltration, 340-342, 399
- Local nerve blocks. See *Regional and local blocks.*
- Loss of resistance, identifying with saline or air, 74
- Lumbar epidural analgesia. See *Epidural analgesia.*
- Lumbar epidural steroid therapy. See *Steroid therapy, epidural.*
- Lumbar plexus block, in infants and children, 370

- Lung, effects of pulmonary embolism. See *Pulmonary effects of pulmonary embolism.*
- Magnetic resonance imaging (MRI), of
interatrial septal defects, 816
in preoperative neurologic assessment, 649-650
of pulmonary embolism, 875
Mannitol, for reducing brain edema, 543
McGill Pain Questionnaire, 232-239
administration and scoring procedures, 236-237
development and description, 232-235
discriminative capacity of, 238-239
illustration of, 235
short-form of, 239, 240, 398
spatial display of pain descriptors, 233
usefulness of, 237
Measurement of pain, 229-246
Analog Chromatic Continuous Scale, 360
behavioral measures, 241-242
Children's Comprehensive Pain Questionnaire, 360
Children's Hospital of Eastern Ontario Pain Scale, 360
Descriptor Differential Scale, 239, 240
dimensions of pain experience, 229-230
language descriptive of pain, 230-231
McGill Pain Questionnaire, 232-239
physiologic measures, 242
short-form McGill Pain Questionnaire, 239, 240, 398
summary, 242-243
Visual Analogue Scales (VAS), 231-232, 397
Mechanonociceptors, 212-213
Medulloblastomas, 472
Meningiomas, 474
Meperidine, compared with lumbar epidural anesthesia, 60-61
for epidural postoperative analgesia, 325-326
for obstetric pain management, 382
MEPs. See *Motor-evoked potentials (MEPs).*
Methadone, for pediatric analgesia, 365
Microembolization, 781
MK-801 receptor agonist, 461-462, 507, 532
Monitoring. See also *Electroencephalographic monitoring.*
special, for posterior fossa surgery, 485-486
spinal cord surgery, 497-501
venous air embolism, 480-481
Morphine, and enhancement of analgesic effects of dezocine, 304-305
for epidural postoperative analgesia, 324-325
for obstetric pain management, 382, 391-392
for pediatric analgesia, 364
Motor-evoked potentials (MEPs). See also *Sensory-evoked potentials (SEPs).*
anesthesia, effects on, 664, 667, 668, 669
electrophysiologic basis, 659-660
intraoperative monitoring, 673-674
preoperative neurologic assessment, 653
prevention of neurologic injury, 669-673
spinal cord surgery, 500-501, 510
MRI. See *Magnetic resonance imaging (MRI).*
Muscle relaxants, and electroencephalographic monitoring, 709
Myelodysplasia, neuroanesthetic considerations, 547-550
preoperative neurologic assessment, 652-653
Naloxone, for reversing side-effects of opioids, 419, 420, 421, 424
Narcotic agonist-antagonists, for epidural postoperative analgesia, 328-329
Narcotics. See also *Opioids.*
and electroencephalographic monitoring, 708
Nausea and vomiting, after cesarean delivery with neuraxial blockade, 107-108
after opioid anesthesia, 155, 418-420
Needles, spinal, and postdural puncture headache, 165-166
Neonatal spinal anesthesia, 129-144
anatomic considerations, 131-132
apnea as postoperative complication, 141-142
choice of drugs, 137
history, 129-130
indications for use, 130-131
postlumbar puncture headaches, 142
review of clinical experience, 138-141
summary, 142-143
technical details, 132-137
Neuroanesthesia, future of, 727-744
cerebral protection, 733-735
drug delivery systems, 738-739
financial concerns, 736-737
history of anesthesiology, 729-732
intracranial pressure, 730-731
monitoring, 735-737

- neuroanesthesiologists, 732-733
stroke, 738
- Neuroanesthesia and cerebral protection, 453-469. See also *Cerebral protection, resuscitation, and monitoring*; *Pediatric neuroanesthesia*.
- anesthetics and cerebral protection, 462-465
- cerebral physiology, 454-455
- methods for cerebral protection, 458-462
- pathophysiology of cerebral injury, 455-458
- suggested regimens for various clinical situations, 464
- Neurologic injury, caused by regional analgesia, 390-391
- Neuropeptides. See *C-fiber neuropeptides*.
- Neurosurgery. See also *Posterior fossa surgery*; *Preoperative assessment of neurologic function*.
future of, 719-726
brain tumors, 723-724
enhancement of neurologic function, 722
epilepsy, 721
ethical concerns, 719-720
pain, 725
trauma, 725
vascular disease, 722-723
and risk of deep vein thrombosis, 840-841
- Nicardipine, for cerebral resuscitation, 585
- Nifedipine, and pulmonary embolism, 882
- Nimodipine, for cerebral resuscitation, 583-585
- Nitroprusside, and pulmonary embolism, 882
- Nitrous oxide, and electroencephalographic monitoring, 705
in infants and children, 362
for posterior fossa surgery, 485
and pulmonary embolism, 775-776, 882
- NMDA (*N*-methyl-D-aspartate) receptor, control of ion channel complex, 586-587
ischemic cell injury, 456, 532
occurrence, 585
- NMDA (*N*-methyl-D-aspartate) receptor antagonists, 461-462, 532, 587-589
- Nociception, defined, 211, 396
- Nociceptors, characteristics of, 212
mechanonociceptors, 212-213
noncutaneous nociceptors, 216
peripheral receptors, 211-216
polymodal nociceptors, 213
sensitization after tissue injury, 248-250
- Norepinephrine, for treatment of pulmonary embolism, 768, 771-774, 881, 882, 891
- Nuclear magnetic resonance, for determination of cerebral phosphate compounds, 567
- Nursing aspects of acute pain management, 435-443
developing the nursing role, 441-442
education for pain management, 427-428
primary care nurses, 433-437
role of nurse specialist, 428-429, 437-441
consultation, 438-439
education, 439-440
research, 440-441
summary, 442
team approach to pain management, 435-436
- Obstetric pain management, 379-394. See also *Cesarean delivery with neuraxial blockade*; *Labor and epidural analgesia*.
complications of regional analgesia, 390-391
inhalational analgesia, 381-382
ketamine, 384
labor pain pathways, 380
lumbar epidural analgesia, 385-389
narcotics, 383
paracervical block, 389
psychoprophylaxis, 380
pudendal block, 390
regional analgesia, 384-391
sedatives and tranquilizers, 384
spinal narcotics, 391-392
systemic medication, 382-384
transcutaneous electrical nerve stimulation, 380-381
- Opiate receptor antagonists, and resuscitation of spinal cord injuries, 506
- Opioids. See also *Patient-controlled analgesia (PCA)*; *Transdermal therapeutic system (TTS)*-fentanyl.
as adjuvants, in continuous epidural infusion, 76-77
in epidural analgesia for labor, 71-72
in epidural anesthesia for cesarean deliveries, 114-115
administration of, 271-286, 407-409
continuous intravenous infusions, 289, 407-408
oral mucosal administration, 271-273
rectal administration, 273-274
subarachnoid administration, 401-402

Opioids (*Continued*)

- summary, 284
- transdermal administration, 274-284
- combined with epidural steroids, 191-192
- complications of, 417-433
 - due to equipment failure, 426-427
 - hospital acute pain service for prevention of, 427-429
 - nausea and vomiting, 418-420
 - opioid-sparing strategies, 429
 - prevention of, 427-429
 - pruritus, 420-421
 - respiratory depression, 424-426
 - summary, 429-430
 - urinary retention, 422-424
- in continuous spinal anesthesia, 89, 91
- enhancement of epidural anesthesia, 25-26
- epidural, in critically-ill patients, combined local anesthetic-opioid infusions, 406
 - continuous infusion, 406
 - intermittent doses, 403-406
 - side effects, 404-406
- for epidural postoperative analgesia, 324-328
 - alfentanil, 328
 - combined with local anesthetics, 329-332
 - fentanyl, 326-327
 - meperidine, 325-326
 - morphine, 324-325
 - sufentanil, 327-328
- intraspinal, in perioperative period, 145-162
 - benefits, 146-147
 - choice of opioids, 150-151
 - complications, 154-155
 - contraindications, 154
 - drug combinations, 156-157
 - economic issues, 157
 - history, 145-146
 - indications for use, 146-149
 - narcotic infusion checklist, 161-62
 - patient-controlled analgesia, 147-149
 - patient monitoring issues, 151-153
 - postoperative analgesia, 149-150
 - standard order, example, 160
 - subarachnoid vs epidural administration, 147
 - technical considerations, 149-155
- for obstetric pain management, 382
- agonist-antagonist narcotics, 382
- epidural administration, 391-392
- fentanyl, 382
- meperidine, 382
- morphine, 382
- for pediatric analgesia, 364-366

- codeine, 365-366
- fentanyl, 364-365
- methadone, 365
- morphine, 364
- sufentanil, 365
- and pulmonary embolism, 775
- Oral mucosal administration of opioids, 271-273
- Orthopedic surgery, and risk of deep vein thrombosis, 843-844
- Ostium primum (atrial septal defect), 801
- Ostium secundum (atrial septal defect), 799, 801
- Oxygen, and electroencephalographic monitoring, 701-702
- supplemental, following pulmonary embolism, 880

- Pain control, acute, administration of
 - opioids for, 271-286
 - oral mucosal administration, 271-273
 - rectal administration, 273-274
 - summary, 284
 - transdermal administration, 274-284
 - complications of opioid analgesia, 417-433
 - misadventure (equipment failure), 426-427
 - prevention of complications, 427-429
 - side effects, 418-426
 - summary, 429-430
- in critically-ill patients, 395-415
 - assessing the patient's pain, 397-398
 - local anesthesia and regional blocks, 399-401
 - nonsteroidal anti-inflammatory agents, 398
 - pain-related behavior, 395-396
 - regional blocks, 399-401
 - related to complications, outcome, and length of stay, 409-411
 - spinal anesthesia, 401-406
 - systemic analgesia, 407-411
- in infants and children, 359-378
 - acute pain in sickle cell disease, 372
 - nonopioid analgesics, 367
 - nonsteroidal anti-inflammatory drugs, 367-368
 - opioid analgesics, 364-366
 - pain assessment, 359-360
 - pain associated with procedures, 361-363
 - patient-controlled analgesia, 366-367
 - perioperative acute pain, 363-364
 - regional blockade, 368-372
 - summary, 372
 - treatment, 361-372

- measurement of pain, 229-246
 behavioral measures, 241-242
 Descriptor Differential Scale, 239, 240
 dimensions of pain experience, 229-230
 language descriptive of pain, 230-231
 McGill Pain Questionnaire, 232-239
 physiologic measures, 242
 short-form McGill Pain Questionnaire, 239, 240
 summary, 242-243
 Visual Analogue Scales (VAS), 231-232
- new systemic analgesic agents, 299-320
 α_2 -agonists, 312-315
 capsaicin, 315-316
 clonidine, 313-315
 dexmedetomidine, 315
 dezocine, 299-307
 ketorolac, 307-312
 summary, 315-316
- nursing aspects, 435-443
 clinical nurse specialist and, 437-441
 development of the nursing role, 441-442
 primary nurse's role, 436-437
 summary, 442
 team approach to pain management, 435-436
- obstetric pain management, 379-394
 inhalational analgesia, 381-382
 labor pain pathways, 380
 psychoprophylaxis, 380
 regional analgesia, 384-391
 spinal narcotics, 391-392
 systemic medication, 382-384
 transcutaneous electrical nerve stimulation, 380-381
- pain reception and processing, 211-228
 afferent pathways, 221-223
 dorsal horn and afferent processing, 217-221
 origins of pain, 211
 peripheral receptors, 211-216
 summary, 223-224
- patient-controlled analgesia, 287-298
 historical perspective, 287-288
 intravenous patient-controlled analgesia, 291-296
 summary, 296
 traditional analgesic regimes, 288-291
- physiologic consequences of tissue injury, 247-269
 alterations in flexion reflexes, 257
 animal models of persistent pain, 257-259
 central effects, 254-263
 central sensitization, 259-263
 neurogenic inflammation, 251-254
 nociceptor sensitization, 248-250
 pain-producing substances, 250-251
 peripheral effects, 248-254
 receptive field expansion, 255-257
 sensitization of dorsal horn neurons, 255-263
 summary, 263
- postoperative epidural analgesia, 321-337
 alfentanil, 328
 α_2 -agonists, 330-332
 fentanyl, 326-327
 local anesthetics, 321-324
 meperidine, 325-326
 morphine, 324-325
 narcotic agonist-antagonists, 328-329
 opioid-local anesthetic combinations, 329-332
 opioids, 324-328
 sufentanil, 327-328
 summary, 322
- regional and local blocks, 339-357
 brachial plexus block, 350-352
 future developments, 352
 intercostal nerve blocks, 344-346
 interpleural analgesia, 346-350
 local anesthetic wound infiltration, 340-342
 peripheral nerve blocks, 342-344
 summary, 352
- Paracervical block, 389
 Paradoxical embolism, 809-812
 Paravertebral block, 400
 Patent foramen ovale (PFO),
 cerebrovascular accidents and, 810, 812
 and decompression sickness, 813
 defined, 798
 diagnosis, with color Doppler echocardiography, 816
 with transesophageal echocardiography, 802, 816
 incidence, 801-802, 812
 and paradoxical embolism, 809-810
- Patient-controlled analgesia (PCA), 287-298
 adverse reactions and side effects, 295
 in critically ill patients, 408-409
 definition of PCA modes and dosing, 291
 educational and attitudinal problems, 290-291
 historical perspective, 287-288
 individual analgesic requirements, 291-294
 in infants and children, 366-367
 intraspinal opioids vs patient-controlled analgesia, 147-149

- Patient-controlled analgesia (PCA) (*Continued*)
- intravenous patient-controlled analgesia, 291-296
 - during labor, 77-78
 - machine-user interface, 295-296
 - minimal effective analgesic concentration (MEAC), 288-289
 - in obstetric pain management, 389
 - PCA paradigm, 288-290
 - pharmacodynamic factors, 292-293
 - pharmacokinetic factors, 292
 - psychologic factors, 293-294
 - safety and problems, 294-296, 409, 426-427
 - summary, 296
 - traditional analgesic regimes, 288-291
 - PCA. See *Patient-controlled analgesia (PCA)*.
 - PDPH. See *Postdural puncture headaches*.
 - Pediatric cardiopulmonary resuscitation, 628-629
 - Pediatric neuroanesthesia, 537-562
 - anesthetic considerations, 541-544
 - arteriovenous malformations, 556-559
 - brain mass reduction, 539
 - cerebral blood volume, 538-539
 - cerebrospinal fluid, 539-540
 - craniofacial procedures, 554
 - craniopharyngioma, 554-555
 - craniosynostosis, 553
 - intracranial pressure, 537-540, 541
 - myelodysplasia, 547-550
 - pathophysiology, 540-541
 - physiology, 537-540
 - seizure surgery, 555
 - supratentorial procedures, 550-555
 - ventricular shunts, 545-547
 - Pediatric pain control, 359-378
 - acute pain in sickle cell disease, 372
 - nonopioid analgesics, 367
 - nonsteroidal anti-inflammatory drugs, 367-368
 - opioid analgesics, 364-366
 - oral administration or opioids, 272
 - pain assessment, 359-360
 - pain associated with procedures, 361-363
 - patient-controlled analgesia, 366-367
 - perioperative acute pain, 363-364
 - regional blockade, 368-372
 - summary, 372
 - treatment, 361-372
 - PEEP. See *Positive end-expiratory pressure (PEEP)*.
 - Penile block, in infants and children, 370
 - Peripheral nerve blocks, 342-344
 - miscellaneous blocks, 344
 - sciatic and femoral blocks, 343-344
 - Peripheral receptors, 211-213
 - opioid and α_2 -receptors, 214, 216
 - peripheral sensitization, 213-216
 - Peripheral sensitization, 213-216, 248-254
 - neurogenic inflammation, 251-254
 - nociceptor sensitization, 248-250
 - pain-producing substances, 250-251
 - Persistent pain, animal models of, 257-259
 - PFO. See *Patent foramen ovale (PFO)*.
 - pH of local anesthetics, changing. See *Carbonation and alkalization of local anesthetics*.
 - Phantom limb pain, 257-259, 258
 - Phencyclidine receptor agonist, 461-462, 532
 - Phenothiazines, for obstetric pain management, 384
 - Phenoxybenzamine, 423
 - Phlegmasia alba dolens, 851
 - Phlegmasia cerulea dolens, 851
 - Physical examination. See *Preoperative assessment of neurologic function*.
 - Physiologic consequences of tissue injury, 247-269
 - alterations in flexion reflexes, 257
 - animal models of persistent pain, 257-259
 - central effects, 254-263
 - central sensitization, 259-263
 - neurogenic inflammation, 251-254
 - nociceptor sensitization, 248-250
 - pain-producing substances, 250-251
 - peripheral effects, 248-254
 - receptive field expansion, 255-257
 - sensitization of dorsal horn neurons, 255-263
 - summary, 263
 - Plasminogen activators, released by
 - pneumatic leg compression, 837, 838
 - Platelet aggregation inhibitors, 854-855
 - Pneumatic leg compression, for
 - preventing deep vein thromboembolism, 836-838
 - failure in cancer patients, 838
 - general surgery, 840
 - gynecologic surgery, 842-843
 - neurosurgery, 840, 841
 - orthopedic surgery, 843-844
 - release of plasminogen activators, 837
 - trauma patients, 846
 - urologic surgery, 842
 - Positions, surgical, park bench and lateral
 - positions, 476-477
 - posterior fossa surgery, 476-478
 - prone, 478
 - sitting position, 477-478, 478-479, 673
 - spinal cord surgery, 502
 - Positive end-expiratory pressure (PEEP),
 - air embolism and, 482-483, 812-813
 - effect on atrial dynamics, 808

- as supportive treatment following pulmonary embolism, 880
- Positron emission tomography, in preoperative neurologic assessment, 651
- Postdural puncture headaches, 163-178
 - caused by large-gauge needles, 94-95
 - clinical presentation, 164-165
 - common complication of epidural anesthesia, 116-117
 - differential diagnosis, 165
 - in infants and children, 95, 96, 142
 - pathophysiology, 163-164
 - prevention, 165-167
 - ambulation after dural puncture, 167
 - small spinal needle diameter, 165
 - spinal needle bevel orientation, 166
 - spinal needle tip design, 166
 - after regional anesthesia for obstetric pain management, 391
 - spontaneous low cerebral spinal fluid pressure headache, 174
 - summary, 174
 - treatment, 167-173
 - caffeine therapy, 168-169
 - epidural blood patch, 169-173
 - epidural saline, 167-168
 - unusual managements, 173-174
- Posterior fossa surgery, 471-491
 - air embolism, 478-483
 - anatomy of posterior fossa, 471-472
 - anesthesia, 483-487
 - congenital malformations, 472
 - intra- and extra-axial lesions, 472-474
 - monitoring with sensory-evoked potentials (SEPs), 671
 - positioning and intraoperative considerations, 476-478
 - preoperative assessment, 475-476
 - vascular lesions, 474-475
- Postoperative epidural analgesia. See under *Epidural analgesia*.
- Potassium, as cause of pain sensitization, 251, 253
- Pregnancy, urokinase thrombolytic therapy and, 889
- Preoperative assessment of neurologic function, 645-656
 - autonomic nervous system function, 648
 - head-injured patients, 605-611
 - imaging techniques, 648-649, 651, 653
 - intracranial pressure, 645-647
 - pediatric neuroanesthesia, 542
 - posterior fossa surgery, 475-476
 - respiratory and cardiovascular centers, 647-648
 - specific disorders, 650-653
- Propofol, and electroencephalographic monitoring, 708
- Prostaglandin inhibitors, for cerebral protection, 462, 590
- Prostaglandins, as cause of pain sensitization, 251, 254
- cell destruction after ischemia, 589-590
- Protein kinases, and central sensitization, 260, 261
- Proto-oncogenes, and central sensitization, 262-263
- Pruritus, after opioid anesthesia, 155, 420-421
- Pudendal block, for obstetric pain management, 390
- Pulmonary angiography, for diagnosis of pulmonary thromboembolism, 872-873
- Pulmonary effects of pulmonary embolism, 781-793
 - acute thromboembolization, 782-789
 - chronic thromboembolization, 789-791
 - gas exchange, 784-789, 790-791
 - lung mechanics, 782-784, 789-790
 - pulmonary arterial hypertension, 766, 881
 - pulmonary edema, 783
- Pulmonary embolectomy, 889-892
 - anesthetic management for, 891-892
 - mortality rates, 890
 - transvenous catheter embolectomy, 892
 - using cardiopulmonary bypass, 890, 891, 895
- Pulmonary embolism, 869-904. See also *Deep vein thrombosis; Embolism and anesthesia*.
 - algorithms for anticoagulation therapy, 883, 884
 - anesthesia and, effect of anesthetic technique, 894-895
 - in hypertensive patients, 775-776
 - anesthetic management for embolectomy, 891-892
 - calf vein thrombosis, 872
 - cardiopulmonary changes after, 878-879
 - central vein or right heart thrombosis, 872
 - chest roentgenogram, ECG, and laboratory tests, 877-878
 - chronic pulmonary thromboemboli, 895-896
 - definitive treatment, 882-893
 - determinants of severity, 756-757
 - diagnosis, 872-876
 - Bone's schema for noninvasive diagnosis, 877
 - criteria for probability assessment, 873-876

Pulmonary embolism (*Continued*)

- invasive and noninvasive methods, 876
- magnetic resonance imaging (MRI), 875
- pulmonary angiography, 872-873
- ventilation/perfusion (V/Q) scans, 873-876
- hemodynamic management, 771-775
- hemodynamic result of, 770-771, 879
- heparin therapy, 882-883, 885-886
- inferior vena cava or femoral "floating" thrombi, 872
- inferior vena cava procedures, 892-893
- intraoperative presentation of, 893-894
- mortality, 869
- origins, 755, 824, 871-872
- pulmonary embolectomy, 889-891
- respiratory changes following, 878
- right ventricular performance in, 757-758, 764-769, 879
- risk factors, 756, 870-871
- signs and symptoms, 876-878
- supportive treatment, 880-882
 - inotropes, 880-881
 - oxygenation and ventilation, 880
 - vasoactive mediators, 881-882
 - volume administration, 880
- thrombolytic therapy, 886-889
- transvenous catheter embolectomy, 892
- types of emboli, 782
- Pulmonary function/complications, preventing, 409-410
- Pulmonary system. *See* Respiratory system
- Pulmonary vascular bed, in pulmonary embolism, 769-771

Quisqualate receptor, 585, 588

Rectal administration of opioids, 273-274

- Regional and local blocks, 339-357
 - brachial plexus block, 350-352, 369, 401
 - cervical plexus block, 368
 - complications, 390-391
 - in critically-ill patients, 399-401
 - epidural, in infants and children, 371-372
 - femoral nerve block, 370
 - future developments, 352
 - ilioinguinal/iliohypogastric block, 369-370
 - in infants and children, 368-372
 - intercostal nerve blocks, 344-346, 369, 399-400

interpleural analgesia, 346-350, 368-369, 400-401

- intravenous regional block, 369
- local anesthetic, 340-342, 368, 399
- lumbar epidural analgesia, 385-389
- lumbar plexus block, 370
- for obstetric pain management, 384-391
- paracervical block, 389
- paravertebral block, 400-401
- penile block, 370
- peripheral nerve blocks, 342-344
- principles, 384-385
- puddend block, 390
- sciatic nerve block, 370
- summary, 352
- Regional anesthesia, and thromboembolic disease, anticoagulant therapy and, 855-857
 - beneficial effects, 851-853
 - compared with general anesthesia, 853
 - effect in deep vein thromboembolism, 893-895
 - lower extremity blood flow, 852
- Respiratory effects of analgesia/anesthesia, clonidine, 314-315
 - dezocine, 303-305
 - ketorolac, 310
 - opioids, 154, 404-406, 424-426
 - TTS-fentanyl therapy, 278, 279, 283
- Respiratory system, impairment, due to spinal cord injury, 505
 - preoperative neurologic assessment, 647-648
 - pulmonary response to head injury, 610-611
- Resuscitation, 575-601. *See also* *Cardiopulmonary resuscitation and cerebral outcome.*
 - cellular physiology, 577-580
 - drug therapy for spinal cord injury, 505-508
 - ischemia, 575-577
 - pathophysiology of ischemia, 580-595
 - of right ventricle, in pulmonary embolism, 761-764
- Right ventricle, in pulmonary embolism, anatomy and physiology, 758-761
 - compared with left ventricle, 759
 - failure due to circulatory collapse, 759-761, 879
 - function and performance, 757-758, 764-766
 - impact of therapy, 766-769
 - resuscitation, 761-764
- Risk factors for embolism, 838-847
 - common risk factors, 756
 - criteria for diagnostic probability assessment, 874

- deep vein thrombosis and pulmonary thromboembolism, 870-871
- general risk factors, 823-824, 870-871
- high-risk patients, 839, 871
- hypercoagulability, 870
- low-risk patients, 838-839, 870
- moderate-risk patients, 838-839, 870
- previous history of deep vein thrombosis, 823
- for surgical procedures, general surgery, 839-840, 870-871
- gynecologic surgery, 842-843
- neurosurgery, 840-841
- orthopedic surgery, 843-844
- urologic surgery, 841-842
- trauma patients, 844-846
- Virchow's risk factors, 823, 870, 871
- Ropivacaine, for obstetric pain management, 387-388
- Saline, for identifying loss of resistance, 74
- as therapy for postdural puncture headaches, 167-168
- Schwannomas, 473-474
- Sciatic nerve block, in infants and children, 370
- Scoliosis, surgical correction, 508-509
- Second messenger systems, and central sensitization, 260-262
- Secondary hyperalgesia. *See Hyperalgesia, secondary.*
- Sedation, after opioid intraspinal anesthesia, 155
- Sedatives, in critically ill patients, 407
- for obstetric pain management, 384
- Sensitization. *See Central sensitization; Peripheral sensitization.*
- Sensory-evoked potentials (SEPs). *See also Motor-evoked potentials (MEPs); Somatosensory-evoked potentials (SSEPs).*
- anesthesia, effects on, 663-664, 668, 669
- classification and common modalities, 658-659
- electrophysiologic basis, 657-658
- equipment requirements for obtaining, 660
- interpretation, 661
- intraoperative monitoring of neurologic procedures, 669-673, 735
- measuring depth of anesthesia, 662-663
- preoperative neurologic assessment, 653
- prevention of neurologic injury, 669-673
- variables in intraoperative recording, 661-662
- SEPs. *See Sensory-evoked potentials (SEPs).*
- Septic embolization, 782, 813
- Septum. *See Interatrial septum and systemic embolism.*
- Serotonin, pain sensitization caused by, 251
- Shivering, after epidural anesthesia for cesarean delivery, 116
- Shunting, and gas exchange, following pulmonary embolism, 784, 786, 788
- interatrial septal communications, 805-809
- Sickle cell disease, acute pain in, 372
- Sinus venosus (atrial septal defect), 801
- Sitting position, danger of air embolism, 478-479
- monitoring with sensory-evoked potentials (SEPs), 673
- omitting nitrous oxide, 485
- posterior fossa surgery, 477-478
- Skull x-rays, and preoperative neurologic assessment, 647
- Somatosensory-evoked potentials (SSEPs). *See also Sensory-evoked potentials (SEPs).*
- anesthesia, effects on, 664, 665-666
- intraoperative monitoring of neurologic procedures, 671-673
- spinal cord surgery, 498-500, 509-510
- subarachnoid hemorrhage surgery, 528-529
- Spinal anesthesia. *See Epidural and spinal anesthesia.*
- Spinal anesthesia, continuous. *See Continuous spinal anesthesia.*
- Spinal anesthesia, total, caused by regional analgesia, 390
- Spinal cord. *See also Dorsal horn neurons.*
- blood flow, effect of epinephrine, 23-24
- injury, and deep vein thrombosis, 845, 846
- Spinal cord surgery anesthesia, 493-519
- acute spinal cord injury, 503-508
- blood supply, anatomy, 493-495
- anesthesia effects, 497
- physiology, 495-497
- regulation, 496
- decompression of spinal cord, 501-503
- intraoperative monitoring, 497-501
- monitoring with sensory-evoked potentials (SEPs), 669-670
- preoperative neurologic assessment, 652
- scoliosis, 508-509
- thoracoabdominal aorta surgery, 509-510
- Spinal headaches. *See Postdural puncture headaches.*
- Spinal needles, and postdural puncture headache, 165-166
- Spinal shock, 504-505

- Spontaneous low cerebral spinal fluid pressure headache, 174
- SSEPs. See *Somatosensory-evoked potentials (SSEPs)*.
- Steroid therapy, epidural, 179-203
cervical epidural steroids, 187-191
complications, 197-200
history, 180-181
lumbar epidural steroids, 181-187
mechanism of action, 192-197
opiates combined with epidural steroids, 191-192
summary, 200-201
- Steroids, 21-aminosteroids, 594
corticosteroids for cerebral protection, 462, 594-595
resuscitation of spinal cord injuries, 505-506
- Streptokinase, compared with pulmonary embolectomy, 890
thrombolytic therapy of pulmonary embolism, 886-889
treatment of deep vein thrombosis, 848
- Stroke, 738, 810, 812
- Subarachnoid administration, of opioids, 401-402
of other agents, 406
- Subarachnoid hemorrhage therapy, 521-536
anesthetic management, 529-531
cerebral protection, 531-532
clinical presentation, 524
history and pathophysiology, 521-524
preoperative diagnosis, 524-525
rebleeding, 523, 526, 531
risk of surgery, 524
sentinel headaches, 523, 524
surgical management, 525-529
vasospasm, 523-524, 525, 526, 584
- Subarachnoid test solutions, 55-56
- Substance P, and neural sensitization, 214, 253-254, 259-260
- Sufentanil, for epidural postoperative analgesia, 327-328
for pediatric analgesia, 365
- Supratentorial procedures, neuroanesthetic considerations, 550-555
- Surgical risk factors for embolism. See *Risk factors for embolism*.
- Surgical therapy of deep vein thrombosis, 851
- Sympathomimetics. See *Epinephrine and other sympathomimetics*.
- Systemic analgesic agents, 299-320
 α_2 -agonists, 312-315
capsaicin, 315-316
clonidine, 313-315
dexmedetomidine, 315
dezocine, 299-307
ketorolac, 307-312
opioids, 407-409
sedatives, 407
summary, 315-316
- Systemic embolism. See *Interatrial septum and systemic embolism*.
- Tachyphylaxis, reduction of, 21
- Temperature, and
electroencephalographic monitoring, 703
homeostasis, in pediatric patients, 544
- Test doses, 45-58
alternatives, 53-56
air, 54
ephedrine, 54-55
isoproterenol, 53-54
local anesthetics, 53
subarachnoid test solutions, 55-56
- epinephrine as an adjuvant, 20-21
problems, 47-53
in anesthetized patients, 52-53
 β -blockade interference, 47-48
in elderly patients, 52
in pregnant patients, 48-52, 74
standard test dose, 45-46
summary, 55-56
- Tetracaine, hyperbaric, in neonatal spinal anesthesia, 137-139
- Third messenger systems, and central sensitization, 262-263
- Thoracoabdominal aorta surgery, 509-510, 673
- Thoracotomy, interpleural analgesia for, 347-349
- Thrombocytopenia, as complication of
heparin therapy, 848, 885
- Thrombolytic therapy, 886-889
contraindications, 886
and neuraxis blockade, 6
selected regimens, 887
streptokinase, 848, 886-889, 890
tissue plasminogen activator (TPA), 769, 774-775, 886-888
urokinase, 848, 886-889
- Time-domain analysis, of
electroencephalograms, 693-695
- Tissue injury. See *Physiologic consequences of tissue injury*.
- Tissue plasminogen activator (TPA), effect on right ventricular function, 769, 774-775
thrombolytic therapy of pulmonary embolism, 886-888
- Tocainide, and thromboembolic disease, 854

- TPA. See *Tissue plasminogen activator (TPA)*
- Tranquilizers, for obstetric pain management, 384
- Transcutaneous electrical nerve stimulation, 380-381, 401
- Transdermal therapeutic system (TTS)-fentanyl, 274-284
 advantages and disadvantages, 274-275
 analgesic effects, 277-282
 arterial blood gas measurements during, 280
 comparative studies, 277-279, 282
 conclusion, 282
 pharmacokinetics, 276-277
 respiratory depression, 278, 279, 283
 schematic of membrane permeation system, 275
 side effects, 278-279
 Visual Analogue Scale measurement, 280-281
- Transesophageal echocardiography. See under *Echocardiography*.
- Traumatic injury, and risk of deep vein thrombosis, 844-846
- TTS-fentanyl system. See *Transdermal therapeutic system (TTS)-fentanyl*.
- Ultrasonography, for diagnosis of deep vein thrombosis, B-mode ultrasonography, 828-830
 Doppler ultrasonography, 827
- Uncal herniation, after head injury, 606-607
- Urinary retention, after opioid anesthesia, 155, 422-424
- Urokinase, thrombolytic therapy of pulmonary embolism, 886-889
 treatment of deep vein thrombosis, 848
- Urologic surgery, and risk of deep vein thrombosis, 841-842
- Uterine smooth muscle and blood flow, effect of epinephrine, 23
- $\dot{V}A/\dot{Q}$ inequality. See *Ventilation/perfusion ($\dot{V}A/\dot{Q}$) inequality*.
- VAS. See *Visual Analogue Scales (VAS)*.
- Vascular lesions, future therapeutic methods, 722-723
 in posterior fossa, 474-475
- Vasodilators, detrimental effects in pulmonary embolism, 768, 882
 for pulmonary arterial hypertension, 763
- Vena cava. See *Inferior vena cava*.
- Venography, for diagnosis of deep vein thrombosis, 825, 876
- Venous cannulation, epidural, 105-106
- Ventilation, after head injury, 611-613
 during posterior fossa surgery, 485
- Ventilation/perfusion (\dot{V}/\dot{Q}) scans, for diagnosis of pulmonary embolism, 873-876
- Ventilation/perfusion ($\dot{V}A/\dot{Q}$) inequality, following pulmonary embolism, 784-789, 790-791
- Ventricular shunts, in pediatric patients, 545-547
- Visceral pain, 216
- Visual Analogue Scales (VAS), assessment of TTS-fentanyl therapy, 280-281
 clinical use, 231-232
 in critically-ill patients, 397
 pediatric assessment, 359-360
- Visual-evoked potentials (VEPs), 658
- Volume administration, as therapy for pulmonary embolism, 767, 880
- Wake-up test, in spinal cord surgery, 497-501
- Warfarin anticoagulation, for deep vein thrombosis, guidelines for therapy, 849
 orthopedic surgery, 843
 overlapping heparin and warfarin therapy, 847-848
- Warming, of epidural anesthetics, 116
 of local anesthetics, 16
- Water, as an adjuvant in local anesthetics, 16-17
- Wide dynamic range (WDR) neurons, 218-219
- Wound infiltration by local anesthetics, 340-342, 399